BRCA2 and breast cancer: In one case (M298), the variant (c.9104A>C, p.Tyr3035Ser) in BRCA2 has been reported previously to reduce BRCA2 protein activity and increase BC risk, however conflicting interpretations of its pathogenicity exist [35].